Kyntra Bio
KYNB
133 hedge funds and large institutions have $637M invested in Kyntra Bio in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 23 closing their positions.
41% more call options, than puts
Call options by funds: $3.24M | Put options by funds: $2.29M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more capital invested
Capital invested by funds: $518M → $637M (+$119M)
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
9% less funds holding
Funds holding: 146 → 133 (-13)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.51M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$5.11M |
| 3 |
TAAM
Top Ace Asset Management
Hong Kong
|
+$4.66M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$4.24M |
| 5 |
Renaissance Technologies
New York
|
+$4.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$12.8M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$6.49M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$4.65M |
| 4 |
JP Morgan Chase
New York
|
-$3.88M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.77M |
KYNB Hedge Fund Activity: Q3 2016 in Review
133 of the 3,758 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2016, worth a combined $637M — up 23% from $518M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KYNB and 12 opened new positions — a net loss of 11 holders — while 42 trimmed existing stakes and 48 added.
The largest buyer was Vanguard Group, adding an estimated $5.51M. The largest seller was Goldman Sachs, cutting an estimated $12.8M.
- 133 institutional investors held Kyntra Bio (KYNB) as of Q3 2016, down from 146 in Q2 2016.
- Funds reported $637M of Kyntra Bio stock for Q3 2016, up 23% quarter-over-quarter.
- 12 funds opened new Kyntra Bio positions in Q3 2016 and 23 closed out, a net change of -11 holders.
- The largest Kyntra Bio buyer in Q3 2016 was Vanguard Group, an estimated $5.51M added.
- The largest Kyntra Bio seller in Q3 2016 was Goldman Sachs, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2016.